<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579096</url>
  </required_header>
  <id_info>
    <org_study_id>594</org_study_id>
    <nct_id>NCT02579096</nct_id>
  </id_info>
  <brief_title>CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat</brief_title>
  <official_title>CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum&#xD;
      uric acid and therefore prevent further gout attacks. These therapies have never been&#xD;
      compared at appropriate doses. Further, they will be studied in patients with kidney disease&#xD;
      for the first time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout is the most common form of inflammatory arthritis affecting adults (1), with a disease&#xD;
      frequency that continues to increase dramatically (2). Gout is associated with substantial&#xD;
      morbidity and mortality which are concentrated in older men and magnified in patients with&#xD;
      chronic kidney disease (CKD) (3-6), demographics common to the Veterans Affairs (VA) Health&#xD;
      System. Effective gout therapies are readily available and are centered primarily on the use&#xD;
      of approved urate lowering therapy (ULT). Despite having excellent ULT options available to&#xD;
      patients (7), gout is extremely poorly managed especially in patients with CKD (8-10).&#xD;
&#xD;
      The two most widely used ULTs in clinical practice, allopurinol and febuxostat, have recently&#xD;
      been endorsed as the two acceptable first-line treatment strategies in chronic gout (7).&#xD;
      Although both agents appear to be efficacious and generally well-tolerated, allopurinol and&#xD;
      febuxostat have significantly different costs and have never been compared to each other at&#xD;
      appropriate doses. Randomized controlled trials completed to date comparing allopurinol with&#xD;
      febuxostat in gout have used 'fixed' and, in many cases, insufficient doses of allopurinol&#xD;
      (11-13), an approach that is contrary to current guideline recommendations (7). Furthermore,&#xD;
      these studies have included only very small proportions of gout patients with CKD even though&#xD;
      CKD is present in approximately 1 of every 2 gout sufferers (14).&#xD;
&#xD;
      To test the hypothesis that allopurinol is non-inferior to febuxostat in the treatment of&#xD;
      gout, the investigators propose a randomized open-label non-inferiority trial, which for the&#xD;
      first time compares allopurinol with febuxostat using appropriately titrated doses and a&#xD;
      &quot;treat-to-target&quot; approach. Further, the investigators will assess the comparative&#xD;
      effectiveness of these agents in a significant number of gout patients with co-morbid CKD.&#xD;
&#xD;
      The investigators plan to enroll 950 participants with a diagnosis of gout, including&#xD;
      participants with stage 3 CKD, who are hyperuricemic defined as a serum uric acid&#xD;
      concentration (sUA) above 6.8 mg/dl. Participants will be recruited from 18 Veteran Affairs&#xD;
      and 5 Rheumatology and Arthritis Investigational Network (RAIN) sites. The total duration of&#xD;
      the trial will be 4 years. Recruitment will occur over 24 months. Participants will be&#xD;
      followed for 72 weeks. This will include a 24 week Dose Titration Phase (Phase 1) followed by&#xD;
      a 24 week Maintenance and Optimization Phase (Phase 2) and then a 24 week Steady State Flare&#xD;
      Observation Phase (Phase 3). The investigators will use a &quot;treat-to-target&quot; approach with&#xD;
      specified titration of ULT dosing to obtain goal sUA. Maximal daily drug doses will be 800&#xD;
      mg/day for allopurinol or 120 mg/day for febuxostat.&#xD;
&#xD;
      The primary outcome will be the proportion of participants who have at least one gout flare&#xD;
      in the allopurinol group compared to the febuxostat group during Phase 3. This primary&#xD;
      outcome was endorsed by the patient and VA provider groups that were surveyed (see below).&#xD;
      All participants will be followed during Phase 3 regardless of the achievement of sUA goal.&#xD;
      The primary hypothesis will test the non-inferiority of allopurinol with regards to&#xD;
      proportions of flares. The investigators anticipate that approximately 15 to 20% of patients&#xD;
      will flare during Phase 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group</measure>
    <time_frame>Phase III of the study (months 12-18 of study duration)</time_frame>
    <description>Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">950</enrollment>
  <condition>Gout</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Allopurinol / Sham Comparator (Febuxostat)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat / Sham Comparator (Allopurinol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Patients will be titrated up to the dose that will lower to target uric acid levels.</description>
    <arm_group_label>Allopurinol / Sham Comparator (Febuxostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat will be titrated up to the dose that will lower to target uric acid levels.</description>
    <arm_group_label>Febuxostat / Sham Comparator (Allopurinol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, vehicle control (Febuxostat-shaped)</intervention_name>
    <description>Placebo in the shape of Febuxostat will be given with Allopurinol</description>
    <arm_group_label>Allopurinol / Sham Comparator (Febuxostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, vehicle control (Allopurinol-shaped)</intervention_name>
    <description>Placebo in the shape of Allopurinol will be given with Febuxostat</description>
    <arm_group_label>Febuxostat / Sham Comparator (Allopurinol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years&#xD;
&#xD;
          -  History of gout - crystal proven or historical as defined by ACR criteria listed above&#xD;
&#xD;
          -  Serum urate level 6.8 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage 4 or 5 Chronic Kidney Disease (CKD) - defined as eGFR of &lt;30 ml/min&#xD;
&#xD;
          -  Women less than 50 years of age&#xD;
&#xD;
          -  Patients with a history of prior solid organ / hematopoietic transplantation&#xD;
&#xD;
          -  Previous allergy or intolerance to allopurinol or febuxostat&#xD;
&#xD;
          -  Patients who are not candidates for any of the recommended prophylactic medications&#xD;
             (colchicine, naprosyn or glucocorticoids)&#xD;
&#xD;
          -  Patients who in the opinion of the investigator have a high genetic risk for&#xD;
             allopurinol hypersensitivity syndrome (AHS*) unless they have been found to be&#xD;
             negative for HLA B5801.&#xD;
&#xD;
          -  Previous history of failure to reach target uric acid levels despite therapy with&#xD;
             allopurinol at dose &gt; 300 mg/day&#xD;
&#xD;
          -  Prior febuxostat use&#xD;
&#xD;
          -  Patients with malignancies that are currently active with exception of non-melanoma&#xD;
             skin cancer&#xD;
&#xD;
          -  Patients with serum uric acid levels &gt;15 mg/dl&#xD;
&#xD;
          -  Patients with myelodysplasia and hemoglobin of &lt; 8.5 g/dL&#xD;
&#xD;
          -  Patients with chronic liver disease with more than one of the following:&#xD;
&#xD;
               -  INR 1.7, not on Warfarin therapy&#xD;
&#xD;
               -  Bilirubin 2 mg/dL&#xD;
&#xD;
               -  Serum albumin &lt;3.5 g/dL&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Encephalopathy&#xD;
&#xD;
          -  Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, or&#xD;
             probenecid&#xD;
&#xD;
          -  Patient who are unable to give informed consent&#xD;
&#xD;
          -  Enrollment in another randomized interventional clinical trial&#xD;
&#xD;
          -  Any severe medical condition that, in the enrollee's opinion, is likely to compromise&#xD;
             the participant's ability to complete the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R O'Dell</last_name>
    <role>Study Chair</role>
    <affiliation>Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System, Loma Linda, CA</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester MN ? RAIN 1</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center, Kansas City, MO</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center ? RAIN 5</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville VA Medical Center, Asheville, NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center ? RAIN 2</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center, Cincinnati, OH</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yankton Medical Clinic ? RAIN 3</name>
      <address>
        <city>Yankton</city>
        <state>South Dakota</state>
        <zip>57078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center, White River Junction, VT</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center, Salem, VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02579096/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

